David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

NZ stocks end flat as US Fed decision looms
Markets Market Close

NZ stocks end flat as US Fed decision looms

Market finishes slightly down as telco company Spark loses more ground.

Jamie Gray 12 Sep 2025
Locate Technologies plans to quit ASX for NZX
Markets

Locate Technologies plans to quit ASX for NZX

Bitcoin-favouring Locate Technologies eyes move to NZX's main board.

Staff reporters 12 Sep 2025
Vital takeover bid passes threshold at 11th hour
Markets

Vital takeover bid passes threshold at 11th hour

Tait International has secured acceptances to meet the 90% minimum condition for its Vital takeover less than a day before the offer was set to expire.Vital filed a substantial product holder (SPH) notice to the NZX on Friday morning, which showed Tait's stake lifted to 92.1%...

Gregor Thompson 12 Sep 2025
Tower again hikes FY underlying profit outlook
Markets

Tower again hikes FY underlying profit outlook

Insurer sees FY underling profit up as large events weigh less than expected     

Staff reporters 12 Sep 2025